BioSpace News Archive

Retinal Biologics Market value surpassed US$ 19.96 Bn in 2022 and projected to grow at 10.7% y-o-y in 2019, as per a new Future Market Insights study.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that CEO Nawal Ouzren will attend in person two investor meetings in April 2022.

PureTech Health plc announced the publication of preclinical proof-of-concept demonstrating that PureTech’s Glyph platform can enhance the oral bioavailability of buprenorphine, a clinically-validated opioid replacement therapy, further expanding the range of clinically-validated drug classes shown to be amenable to the Glyph technology.

ReiThera Srl and Exothera announced that they have entered into a collaboration agreement to develop a large-scale, low cost per dose manufacturing process for the production of ReiThera’s novel vaccines.

The Annual General Meeting of Promore Pharma AB will be held on Tuesday, 17 May 2022 at 2 pm, in the premises of Wennergren Center, Biblioteket, floor 24, Sveavägen 166, in Stockholm.

Deerfield Partner Andrew ElBardissi, M.D. and Petrichor Partner Patrick Lally to Join Aurion Biotech Board Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, announced it has secured a $120 million financing with top-tier biotech and ophthalmology investors.

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for pegzilarginase for the treatment of Arginase 1 Deficiency.

Fera is pleased to announce that FDA has granted Orphan Drug Designation for Phospholine Iodide as a treatment for Stargardt disease.

Exai Bio, a next-generation liquid biopsy company, is presenting data from its scientific research program on the discovery and validation of tumor-specific, orphan non-coding RNAs, and the validation of artificial intelligence profiling of oncRNAs to accurately detect cancers of diverse tissue origins.

Myovant Sciences and Pfizer announced an update on the Supplemental New Drug Application for MYFEMBREE® for the management of moderate to severe pain associated with endometriosis.